Thursday 18 May 2023

Thursday 18 May

08:00 - 08:45 Educational Session 3


Normal sympathetic nervous system development: From organoid and zebrafish to humanized mouse

Susanne Schlisio, Sweden


Heterogeneity in clinical course of NB: broad overview: clinical behaviour - disease course

Meredith Irwin, Canada

09:00 - 10:00 Plenary session 6: Genetic drivers of resistance and relapse

Sponsored by Neuroblastoma UK, Moderators: Gudrun Schleiermacher, France & John Maris, United States


PS6.1 Investigating neuroblastoma evolution by matched diagnosis, relapse and cfDNA sequencing as part of the Stratified Medicine for Paediatrics study (SMPaeds)

Sally George, UK


PS6.2 The transcriptional co-repressor Runx1t1 is essential for N-Myc-driven neuroblastoma tumorigenesis

Murray Norris, Australia


PS6.3 Frequency and clinical significance of subclonal and clonal driver mutations in high-risk neuroblastomas at diagnosis: A Children’s Oncology Group Study.

Esther Berko, United States


PS6.4 Genomic landscape of a national neuroblastoma relapse cohort and its implications

Pascal Kohmann, Germany

10:00 - 10:45 Keynote Lecture 3

Moderator: Katleen de Preter, Belgium


Organoid cellular cancer immunity models in motion

Anne Rios, the Netherlands


10:45 - 11:15 Coffee break

11:15 - 12:05 Parallel session 15: How patient advocates can help improve the survival of children with neuroblastoma

Sponsored by Villa Joep, Solving kids' Cancer and Neuroblastoma UK

11:15 - 12:05 Parallel session 16: Genetic drivers of resistance and relapse

Moderators: Daniel Bexell, Sweden & Esther Berko, Israel


O16.1 Loss of p16INK4a in neuroblastoma induces shift to an immature state with mesenchymal characteristics and increases sensitivity to EGFR inhibitors

Marlinde van den Boogaard, the Netherlands


O16.2 Clonal Decomposition and DNA Replication States Defined by Scaled Single-Cell Genome Sequencing in Neuroblastoma

Jaydutt Bhalshankar, France


O16.3 Direct targeting of RAS via small-molecule inhibition in RAS-driven and lorlatinib-resistant ALK-driven high-risk neuroblastomas

Mark Gerelus, United States


O16.4 A genetic study of paired diagnosis and relapse neuroblastoma samples identifies a novel relapse-specific mutational signature

Lisa Allinson, UK

12:05 - 12:20 Rapid Fire session 2B

Moderator: Katleen de Preter, Belgium


P195 Nucleosome footprinting enables inference of expression profiles in circulating tumor DNA from neuroblastoma patients

Yasmine Iddir, France


P194 The C57 BL/6 Th-ALKF1174L/MYCN genetically-engineered murine model of high-risk neuroblastoma enables the preclinical study of metastatic drug resistant relapse

Lizzie Tucker, UK


P196 Detection of epigenetic cell states in cell-free DNA of high-risk neuroblastoma patients

Lotte Cornelli, Belgium


P193 Comprehensive allelic series of ATRX In-Frame-Fusions in neuroblastoma reveals neomorphic protein functions

Sina Jostes, United States


P299 Surgical Outcome of A Nationwide Phase II Study of Delayed Local Treatment for Children with High-risk Neuroblastoma (JN-H-11)

Akihiro Yoneda, Japan


P300 Late disappearance of minimal residual disease after KIR-ligand mismatched allogeneic CBT suggests KIR mismatched NK cell activity to Neuroblastoma

Nobuhiro Nishio, Japan


P272 Modeling strategies for survival in Neuroblastoma: focus on long-term survival prediction in stage 4 patients >1 year treated within SIOPEN-HR-NBL1

Ulrike Poetschger, Austria


P326 Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA

Jill Deleu, Belgium


P330 Multiplexing of genomic targets for high-risk neuroblastoma MRD diagnostics using mediator probe PCR chemistry

Anna Schroeer, Germany


P331 Longitudinal cell-free DNA analysis in patients with high-risk neuroblastoma is suitable for early relapse and actionable target detection

Marco Lodrini, Germany


12:20 - 13:50 Lunch & Poster Session Group D

Posters with reference P271 until P350

12:20 - 13:50 Lunch meeting I: Managing bone and bone marrow involvement in neuroblastoma with anti-GD2 therapy

This activity is supported by an independent educational grant from Y-mAbs Therapeutics, Inc.


Welcome and introduction

Daniel Morgenstern


Anti-GD2 strategies for high-risk neuroblastoma

Juliet Gray


Expert presentation: High-risk neuroblastoma with bone and bone marrow involvement

Lieve Tytgat


Three interactive short patient case challenges

Case challenge 1
Patient who relapses during immunotherapy maintenance: What to treat with next?
Juliet Gray

Case challenge 2
Treatment options for primary refractory disease in bone and/or bone marrow
Daniel Morgenstern

Case challenge 3
Treatment options for patients with oligometastatic recurrence on MIBG
Lieve Tytgat


Future outlook for antibody therapy

Daniel Morgenstern



Moderated by Daniel Morgenstern


Summary and close

Daniel Morgenstern

12:30 - 13:40 Lunch meeting II: 2035: A High-Risk Neuroblastoma Odyssey

Sponsored by Solving kids' Cancer


Welcome and introduction

Prof Andy Pearson || Presenters: Leona Knox, Prof Rochelle Bagatelle || Panel: Leona Knox, Nick Bird, Advocate (US), Prof Rochelle Bagatelle, Dr Steve DuBois, Prof Maja Beck, Dr Lucas Moreno

Therapy for children with high-risk neuroblastoma has changed dramatically and outcomes have greatly improved in the past decades, but much remains to be done to increase survival rates and decrease late effects of treatment. To move the field forward and improve outcomes for all children with high-risk neuroblastoma, we must develop a vision for neuroblastoma therapy that extends beyond what is right around the corner, and consider the paradigm shifts that will be required to turn our broad vision into reality. Please join us for an interactive session that will be of interest to laboratory-based scientists, neuroblastoma trialists, clinical care providers and parent advocates as we take a birds’ eye view and challenge ourselves to think expansively about how neuroblastoma will be treated in 2035 … and beyond.

13:50 - 14:50 Plenary session 7: Novel diagnostics: liquid biopsies

Moderators: Steven Dubois, United States & Lieve Tytgat, the Netherlands


PS7.1 Liquid biopsies for monitoring tumor evolution and pharmacodynamic assessment of vorinostat effects during neuroblastoma therapy

Anne-Florence Blandin, United States


PS7.2 Quantitative and sensitive neuroblastoma minimal residual disease detection using extrachromosomal DNA (ecDNA) MYCN breakpoints

Annabell Szymansky, Germany


PS7.3 Application of liquid biopsy approaches in neuroblastoma: Whole-exome sequencing and targeted approaches for diagnostic, prognostic and minimal residual disease detection

Zeinab Van Gestel-fadaie, the Netherlands


PS7.4 Integrating correlative biology into a phase III clinical trial for high-risk neuroblastoma to study mechanisms of tumor evolution

Gabriela Virdzekova, United States


Coffee break

15:20 - 16:10 Parallel session 17: Novel diagnostics: imaging

Moderators: Marie Luporsi, France & Mark Gaze, UK


O17.1 Performing [18F]mFBG Long Axial Field Of View (LAFOV) PET-CT without sedation or general anaesthesia for imaging of children with neuroblastoma

Lise Borgwardt, Denmark


O17.2 18F-MFBG PET imaging in patients with neuroblastoma: lesion targeting and comparison with MIBG

Shakeel Modak, United States


O17.3 Prognostic value of tumor heterogeneity in neuroblastoma using pre-treatment MIBG SPECT/CT: is there a place for radiomics?

Marie Luporsi, France


O17.4 Multispectral short-wave infrared (SWIR) fluorescence imaging as a new versatile tool to enhance intra-operative delineation of tumour margins

Laura Privitera, UK

15:20 - 16:10 Parallel session 18: Immune Therapy

Moderators: Paul Sondel, United States & Jan Molenaar, the Netherlands


O18.1 Mastering the game of hide and seek: epigenetic modulation as a strategy to increase T-cell immunogenicity of high-risk neuroblastoma

Annelisa Cornel, the Netherlands


O18.2 Copper chelation disrupts the immunosuppressive neuroblastoma microenvironment to enhance anti-GD2 immunotherapy

Orazio Vittorio, Australia


O18.3 A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate demonstrates potent cytotoxicity in neuroblastoma (NB) and other ALK-expressing cancers

Alberto Guerra, United States


O18.4 Targeting neuroblastoma using Aurora-A inhibition and CAR T-cells

Mareike Müller, Germany


Change rooms

16:20 - 16:45 Scientific highlights ANR2023

16:45 - 17:10 Closing Ceremony


19:00 - 01:00 Congress dinner + party